Insulin glargine, 300 U/ml

DRUG2 trials

Sponsors

Sanofi

Conditions

Diabetes Mellitus, Type 2Type 1 Diabetes Mellitus

Phase 4

A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

CompletedNCT02451137

SanofiDiabetes Mellitus, Type 2

Start: 2015-06-16End: 2018-08-09Updated: 2019-09-10

Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

CompletedNCT04075513

SanofiType 1 Diabetes Mellitus

Start: 2019-10-09End: 2021-09-16Updated: 2022-11-14

Related Papers

105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

Diabetes2022-05-312 citations

Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control.

2020-12-313 citations

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design.

2020-02-2515 citations

Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes

Postgraduate Medicine2016-10-0315 citations